{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:04:50Z","timestamp":1793228690922,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.yrtph.2023.105424","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T15:28:50Z","timestamp":1686151730000},"page":"105424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Carcinogenicity assessment of tegoprazan in Sprague-Dawley (Crl:CD) rats and ICR (Crl:CD1) mice"],"prefix":"10.1016","volume":"142","author":[{"given":"Myeongjoong","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bongtae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geun Seog","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4052-8745","authenticated-orcid":false,"given":"Woo-Chan","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2023.105424_bib1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/gutjnl-2021-325097","article-title":"Proton pump inhibitors and risk of gastric cancer: population-based cohort study","volume":"71","author":"Abrahami","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.yrtph.2023.105424_bib2","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1177\/019262338801600222","article-title":"Gastric ECL-cell hyperplasia and carcinoids in rodents following chronic administration of H2-antagonists SK&F 93479 and oxmetidine and omeprazole","volume":"16","author":"Betton","year":"1988","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2023.105424_bib3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/mutage\/geq025","article-title":"Genotoxic and carcinogenic effects of gastrointestinal drugs","volume":"25","author":"Brambilla","year":"2010","journal-title":"Mutagenesis"},{"key":"10.1016\/j.yrtph.2023.105424_bib4","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1007\/s10620-010-1209-2","article-title":"Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement?","volume":"55","author":"Chey","year":"2010","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.yrtph.2023.105424_bib5","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/apt.15865","article-title":"Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer","volume":"52","author":"Cho","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.yrtph.2023.105424_bib6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.5056\/jnm15105","article-title":"Unmet needs in the treatment of gastroesophageal reflux disease","volume":"21","author":"Dickman","year":"2015","journal-title":"J. Neurogastroenterol. Motil."},{"key":"10.1016\/j.yrtph.2023.105424_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/00401706.1969.10490658","article-title":"Transformations: some examples revisited","volume":"11","author":"Draper","year":"1969","journal-title":"Technometrics"},{"key":"10.1016\/j.yrtph.2023.105424_bib8","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1080\/01621459.1955.10501294","article-title":"A multiple comparison procedure for comparing several treatments with a control","volume":"50","author":"Dunnett","year":"1955","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.yrtph.2023.105424_bib9","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2307\/2528490","article-title":"New tables for multiple comparisons with a control","volume":"20","author":"Dunnett","year":"1964","journal-title":"Biometrics"},{"key":"10.1016\/j.yrtph.2023.105424_bib10","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1136\/gutjnl-2012-304269","article-title":"Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review","volume":"63","author":"El-Serag","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.yrtph.2023.105424_bib11","series-title":"Guidance for Industry, Statistical Aspects of the Design, Analysis, and Interpretation of Chronic Rodent Carcinogenicity Studies of Pharmaceuticals, Draft Guidance","year":"2001"},{"key":"10.1016\/j.yrtph.2023.105424_bib12","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1136\/gutjnl-2016-311715","article-title":"Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus","volume":"65","author":"Fock","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.yrtph.2023.105424_bib13","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/apt.15438","article-title":"Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects","volume":"50","author":"Han","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.yrtph.2023.105424_bib14","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1046\/j.1365-2036.2000.00829.x","article-title":"Proton pump inhibitors: better acid suppression when taken before a meal than without a meal","volume":"14","author":"Hatlebakk","year":"2000","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.yrtph.2023.105424_bib15","article-title":"Influence of proton pump inhibitors on clinical outcomes in coronary heart disease patients receiving aspirin and clopidogrel: a meta-analysis","volume":"97","author":"Hu","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.yrtph.2023.105424_bib16","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/j.1440-1746.2011.06750.x","article-title":"Prevalence of gastroesophageal reflux disease in a general population in Taiwan","volume":"26","author":"Hung","year":"2011","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.yrtph.2023.105424_bib17","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1440-1746.2010.06408.x","article-title":"Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects","volume":"25","author":"Kim","year":"2010","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.yrtph.2023.105424_bib18","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1440-1746.2011.06921.x","article-title":"Prevalence of gastroesophageal reflux disease in Korea and associated health-care utilization: a national population-based study","volume":"27","author":"Kim","year":"2012","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.yrtph.2023.105424_bib19","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1007\/s00535-011-0429-3","article-title":"Systematic review of the epidemiology of gastroesophageal reflux disease in Japan","volume":"46","author":"Kinoshita","year":"2011","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.yrtph.2023.105424_bib20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1600-0773.2004.pto950102.x","article-title":"CYP2C19 polymorphism and proton pump inhibitors","volume":"95","author":"Klotz","year":"2004","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.yrtph.2023.105424_bib21","series-title":"Robust Tests for Equality of Variances, Contributions to Probability and Statistics","author":"Levene","year":"1960"},{"key":"10.1016\/j.yrtph.2023.105424_bib22","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1177\/0192623310373778","article-title":"Hepatic enzyme induction: histopathology","volume":"38","author":"Maronpot","year":"2010","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2023.105424_bib23","first-page":"775","article-title":"The pathobiology of the human enterochromaffin-like cell","volume":"65","author":"Modlin","year":"1992","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.yrtph.2023.105424_bib24","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1293\/tox.29.1S","article-title":"Nonproliferative and proliferative lesions of the gastrointestinal tract, pancreas and salivary glands of the rat and mouse","volume":"29","author":"Nolte","year":"2016","journal-title":"J. Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2023.105424_bib25","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1517\/13543784.14.4.411","article-title":"Novel approaches to the pharmacological blockade of gastric acid secretion","volume":"14","author":"Parsons","year":"2005","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.yrtph.2023.105424_bib26","first-page":"311","article-title":"Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments","author":"Peto","year":"1980","journal-title":"IARC (Int. Agency Res. Cancer) Monogr. Eval. Carcinog. Risks Hum. Suppl."},{"key":"10.1016\/j.yrtph.2023.105424_bib27","series-title":"Review Report for Takecab (Vonoprazan Fumarate)","year":"2014"},{"key":"10.1016\/j.yrtph.2023.105424_bib28","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2169\/internalmedicine.5431-20","article-title":"The development of foveolar-type gastric adenocarcinoma during maintenance therapy of vonoprazan for reflux esophagitis","volume":"60","author":"Saito","year":"2021","journal-title":"Intern. Med."},{"key":"10.1016\/j.yrtph.2023.105424_bib29","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/apt.16121","article-title":"Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects","volume":"52","author":"Sunwoo","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.yrtph.2023.105424_bib30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1124\/jpet.117.244202","article-title":"Tegoprazan, a novel potassium-competitive acid blocker to control gastric acid secretion and motility","volume":"364","author":"Takahashi","year":"2018","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.yrtph.2023.105424_bib31","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.3748\/wjg.v16.i19.2323","article-title":"Safety of the long-term use of proton pump inhibitors","volume":"16","author":"Thomson","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.yrtph.2023.105424_bib32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/CEG.S144149","article-title":"Rationale and design of the VISION study: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis","volume":"11","author":"Uemura","year":"2018","journal-title":"Clin. Exp. Gastroenterol."},{"key":"10.1016\/j.yrtph.2023.105424_bib33","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/j.1365-2036.2004.01957.x","article-title":"Review article: new pharmacological agents for the treatment of gastro-oesophageal reflux disease","volume":"19","author":"Vakil","year":"2004","journal-title":"Aliment. Pharmacol. Ther."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230023000922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230023000922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:36:58Z","timestamp":1759495018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230023000922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":33,"alternative-id":["S0273230023000922"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2023.105424","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carcinogenicity assessment of tegoprazan in Sprague-Dawley (Crl:CD) rats and ICR (Crl:CD1) mice","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2023.105424","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"105424"}}